Top Medical News
8 hours ago
The total number of shockwave therapy significantly affects treatment efficacy, according to a recent study, which has shown improved sexual function in erectile dysfunction patients undergoing 12 vs 6 shockwave therapy sessions.
Pearl Toh, 4 days ago
Frailty is predictive of new-onset urinary incontinence (UI) and death among older adults up to 1 year after hospitalization, a study suggests.
4 days ago
Patients with idiopathic Parkinson’s disease appear to be at a higher risk of overactive bladder, a recent study has shown.
01 Mar 2018
There exists an association between contact surface area (CSA) and the change in postoperative renal function after partial nephrectomy, a recent study has found. CSA can be used together with the nephrometry score to advise patients regarding the risk of renal functional decline after partial nephrectomy.
28 Feb 2018
In chemotherapy-naïve castrate-resistant prostate cancer (CRPC) patients, first- and second-line administration of abiraterone acetate (AA) treatment leads to favourable outcomes, a recent Japan study suggests.
28 Feb 2018
It appears that percutaneous nephrolithotomy is safe and effective in patients maintaining low-dose aspirin treatment perioperatively, according to a recent study.
27 Feb 2018
Supplementation with vitamin D and omega-3 affords reductions in the number of wet nights among 7–15-year-old patients with nocturnal enuresis, a recent study has shown.
Special Reports
02 Nov 2017
Nocturia is the most prevalent of the lower urinary tract symptoms (LUTS) and can cause a significant negative impact on an individual’s quality of life if left untreated.1,2 In a meeting held at University Malaya Medical Centre, Associate Professor Dr Ong Teng Aik shared his insights on the management of nocturia.
Dr Jaime Songco, 31 Oct 2017

Erectile dysfunction (ED) is a common condition defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance.1 It is one of the most common complaints in men’s sexual medicine, affecting both physical and psychosocial health and having a significant impact on the patient and partner’s quality of life.1 Moreover, ED is commonly associated with other comorbid conditions, including hypertension, dyslipidaemia and diabetes mellitus.1

Evaluation of ED should include a detailed medical and sexual history of the patient. 1 A discussion of the patient and partner’s preference and treatment goals is essential to better tailor treatment and improve patient satisfaction and adherence to treatment.2 Lifestyle modification and management of risk factors should precede pharmacotherapy, while first-line treatment with oral phosphodiesterase type 5 inhibitors (PDE5i) is well established for the management of patients with ED.1

28 Sep 2017

Benign prostatic hyperplasia (BPH) is characterized by an enlargement of the prostate gland that can lead to compression of the urethra.1 Patients often experience lower urinary tract symptoms (LUTS), which are typically classified as either voiding or storage symptoms.1

Over 60% of men will experience any LUTS.2  Although Asian men typically have smaller prostates compared with Western men, Asians experience similar or higher rates of LUTS that can impact sexual function and quality of life (QoL).1,3

Professor Zulkifli Md. Zainuddin, 21 Aug 2017
Experience-sharing interview: Managing a case of urinary incontinence
15 Jun 2017
At a recent morning tea symposium held in conjunction with the Malaysian Urological Conference 2016, Dr Marie Carmela Lapitan discussed about the benefits of combination therapy with alpha-blockers and 5-alpha-reductase inhibitors (5-ARIs) for the management of benign prostatic hyperplasia (BPH).
Conference Reports
Audrey Abella, 27 Feb 2018
Enzalutamide may improve the rate of achieving prostate-specific antigen (PSA) remission and consequently, survival outcomes among prostate cancer patients, according to studies presented at the ASCO Genitourinary (ASCO GU) Cancers Symposium 2018.

Dr. Joseph Delano Fule Robles, 27 Feb 2018

Long-term data from the KEYNOTE-045 trial showed ongoing superiority of the programmed death 1 (PD-1) inhibitor pembrolizumab compared with chemotherapy for advanced and metastatic bladder cancer, according to results presented at the ASCO Genitourinary Cancers Symposium 2018 (ASCO GU 2018). 

Dr. Joseph Delano Fule Robles, 23 Feb 2018

Programmed-death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have shown promising results in recent clinical trials in metastatic renal cell carcinoma (mRCC), according to data presented at the Hong Kong Society of Uro-Oncology Annual Scientific Meeting. 

Audrey Abella, 23 Feb 2018
Abiraterone acetate (AA) was associated with improved survival outcomes in prostate cancer treatment and had a favourable toxicity profile, according to several studies presented at the ASCO Genitourinary Cancers Symposium 2018 (ASCO GU 2018).

Roshini Claire Anthony, 22 Feb 2018

The androgen receptor inhibitor apalutamide prolonged metastasis-free survival (MFS) by approximately 2 years in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of metastatic disease, according to findings of the SPARTAN* trial.

Christina Lau, 12 Feb 2018
Chinese patients with metastatic castration-resistant prostate cancer (mCRPC) have higher response rates, longer survival and a lower risk of fatigue when enzalutamide is used in earlier rather than later lines of treatment, a study by the Hong Kong Society of Uro-Oncology has shown.
Christina Lau, 07 Feb 2018
Adding docetaxel to androgen deprivation therapy (ADT) can prevent prostate-specific antigen (PSA) progression and delay the development of castration resistance in Chinese patients with metastatic hormone-naïve prostate cancer, a study by the Chinese University of Hong Kong (CUHK) has shown.